Table 3.

Frequency of drug‐related adverse events in patients with advanced non‐small‐cell lung cancer during protocol treatment with salazosulfapyridine (SASP) in combination with cisplatin and pemetrexed

	SASP dose (g/day)						All patients (n = 15)
	1.5 (n = 6)		3.0 (n = 6)		4.5 (n = 3)
	All grades	Grade ≥3	All grades	Grade ≥3	All grades	Grade ≥3	All grades	Grade ≥3
Non‐hematologic
Anorexia	5 (83)	0 (0)	6 (100)	2 (33)	3 (100)	2 (67)	14 (93)	4 (27)
Fatigue	6 (100)	0 (0)	5 (83)	0 (0)	3 (100)	0 (0)	14 (93)	0 (0)
Nausea	4 (67)	0 (0)	5 (83)	0 (0)	3 (100)	1 (33)	12 (80)	1 (7)
Vomiting	3 (50)	0 (0)	3 (50)	0 (0)	3 (100)	1 (33)	9 (60)	1 (7)
Constipation	4 (67)	0 (0)	4 (67)	0 (0)	1 (33)	0 (0)	9 (60)	0 (0)
Hyponatremia	2 (33)	2 (33)	4 (67)	4 (67)	2 (67)	1 (33)	8 (53)	7 (47)
ALT increased	5 (83)	2 (33)	2 (33)	0 (0)	1 (33)	0 (0)	8 (53)	2 (13)
AST increased	4 (67)	1 (17)	2 (33)	1 (17)	1 (33)	0 (0)	7 (47)	2 (13)
GGT increased	5 (83)	2 (33)	2 (33)	0 (0)	0 (0)	0 (0)	7 (47)	2 (13)
Stomach ache	1 (17)	0 (0)	2 (33)	0 (0)	2 (67)	0 (0)	5 (33)	0 (0)
Hypotension	0 (0)	0 (0)	1 (17)	1 (17)	0 (0)	0 (0)	1 (7)	1 (7)
Pneumonitis	0 (0)	0 (0)	1 (17)	1 (17)	0 (0)	0 (0)	1 (7)	1 (7)
Febrile neutropenia	1 (17)	1 (17)	0 (0)	0 (0)	0 (0)	0 (0)	1 (7)	1 (7)
Hematologic
Anemia	6 (100)	0 (0)	3 (50)	1 (17)	1 (33)	1 (33)	10 (67)	2 (13)
Leukopenia	3 (50)	2 (33)	3 (50)	2 (33)	3 (100)	2 (67)	9 (60)	6 (40)
Neutropenia	4 (67)	3 (50)	3 (50)	3 (50)	2 (67)	2 (67)	9 (60)	8 (53)
Thrombocytopenia	2 (33)	0 (0)	4 (67)	0 (0)	2 (67)	0 (0)	8 (53)	0 (0)

Data are shown as n (%). ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ‐glutamyl transpeptidase.